Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

90.86 +0.69 (+0.77%)
Streaming Delayed Price Updated: 2:16 PM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
74 75 Next >
News headline image
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder ↗
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks. 
Via Benzinga
News headline image
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer ↗
AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression outcomes in treated patients. 
Via Benzinga
News headline image
IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
News headline image
FDA Approves AstraZeneca's Blockbuster Cancer Drug Imfinzi For Aggressive Form Of Lung Cancer ↗
AstraZeneca's Imfinzi gains FDA approval for LS-SCLC after ADRIATIC trial shows survival benefits. Separate trials explore additional cancer therapies. 
Via Benzinga
News headline image
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
From AstraZeneca
Via Business Wire
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons' ↗
 
Via Benzinga
News headline image
3 Momentum Stocks Soaring Into 2025 and Beyond
Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential. 
Via MarketBeat
Topics Stocks
News headline image
Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines. 
Via MarketBeat
Topics Government
News headline image
TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns ↗
FDA panel to discuss AstraZeneca's supplemental application for Andexxa amid safety concerns, including thrombosis risks and efficacy limitations. 
Via Benzinga
News headline image
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now ↗
Via The Motley Fool
News headline image
This AstraZeneca Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
From AstraZeneca
Via Business Wire
News headline image
Not-So-Big Pharma ↗
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
News headline image
European And US Vaccine Stocks Are Under Pressure - Here's WHy ↗
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
News headline image
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It ↗
Altria Group is "undervalued," Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of $1.38. 
Via Benzinga
News headline image
WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill ↗
Trump's decision to appoint Kennedy, known for his vaccine skepticism, has sparked significant attention. 
Via Benzinga
Topics Government
News headline image
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower ↗
Trump may appoint Robert F. Kennedy Jr. as HHS Secretary, stirring mixed reactions. Kennedy's views on vaccines could reshape policies and affect vaccine stocks. 
Via Benzinga
Topics Government
News headline image
Is AstraZeneca a Buy as It Eyes the Weight Loss Market? ↗
AstraZeneca just released some encouraging data about its weight loss drug candidates. 
Via The Motley Fool
News headline image
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease ↗
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options. 
Via Benzinga
News headline image
AstraZeneca Plc (AZN) Q3 2024 Earnings Call Transcript ↗
AZN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously' ↗
AstraZeneca reports $13.57 billion in Q3 sales, up 18% year-over-year. Announces $3.5B U.S. investment to boost R&D and manufacturing with 1,000 new jobs. 
Via Benzinga
News headline image
AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter Beat ↗
AstraZeneca Chief Executive Pascal Soriot said the company is taking the allegations "very seriously." 
Via Investor's Business Daily
News headline image
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca’s 9M and Q3 2024 results
From AstraZeneca
Via Business Wire
News headline image
The Week Kamala Harris Lost (Nov 4-8), These Large Cap Stocks Lost Big ↗
Kamala Harris lost 2024 US election, 10 large-cap stocks performed poorly: Moderna, Honda, Akamai, ADS, AstraZeneca, Pinterest, MercadoLibre, First Solar, POSCO, Floor & Decor 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.